[1] Nevens F. PBC-transplantation and disease recurrence. Best Pract Res Clin Gastroenterol,2018 ,34-35:107-111. [2] 王媛媛,张福民.原发性胆汁性肝硬化临床特征分析.临床医药文献电子杂志,2020,7(15):52. [3] Mattner J. Impact of microbes on the pathogenesis of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Int J Mol Sci,2016 ,17(11):1864. [4] Marzorati S, Lleo A, Carbone M, et al. The epigenetics of PBC: The link between genetic susceptibility and environment. Clin Res Hepatol Gastroenterol,2016,40(6):650-659. [5] 中华医学会风湿病学分会:自身免疫性肝病诊断和治疗指南.中华风湿病学杂志,2011,15(8):556. [6] 刘卫英,肖琳,银皓,等. AMA/AMA-M2 阴性原发性胆汁性肝硬化患者的临床及病理特征. 世界华人消化杂志,2013,21(34):3799-3805. [7] 王尧. 原发性胆汁性肝硬化的临床特点及其合并症的临床资料分析.吉林大学,2018. [8] 刘红丽. 抗线粒体抗体阴性和阳性的原发性胆汁性胆管炎患者临床及病理特征比较.东南大学,2019. [9] Lindor KD,Gershwin ME,Poupon R,et al. Primary biliary cir-rhosis. Hepatology,2009,50(1):291-308. [10] de Liso F, Matinato C, Ronchi M, et al. The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature.Clin Chem Lab Med,2017 ,56(1):25-31. [11] Arenas F, Hervías I, Sáez E,et al. Promoter hypermethylation of the AE2/SLC4A2 gene in PBC. JHEP Rep,2019,1(3):145-153. [12] Tsuneyama K, Baba H, Morimoto Y, et al. Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms. J Med Invest,2017,64(1.2):7-13. [13] Vierling JM. Autoimmune cholangiopathy. Clin Liver Dis,1999,3(3):571-584. [14] 渠畅. 肝硬化患者血清脂类及载脂蛋白变化的临床意义.山东大学,2020. [15] 朱友才, 丁银林, 郁爱俊. 肝硬化和原发性肝癌患者血清IgE检测临床意义. 实用内科杂志, 1991,11(1):20-21. |